Patient no. | Age (y) | Sex | Risk factor | Modified Child-Pugh score | Okuda score | No. of sessions | Previous treatment (interval [wk]) |
---|---|---|---|---|---|---|---|
1 | 71 | M | ALC | B9 | II | 1 | NO |
2 | 71 | M | HCV, ALC | B9 | II | 1 | 131I (16) |
3 | 71 | F | HCV | A5 | I | 3 (a, b, c) | 131I (14) |
4 | 69 | M | ALC | A5 | I | 1 | 131I (16) |
5 | 58 | F | HCV | A5 | I | 1 | NO |
6 | 72 | M | HCV | A5 | I | 2 (a, b) | RFA (52) |
7 | 76 | M | HC | A5 | I | 3 (a, b, c) | NO |
8 | 59 | M | ALC | A6 | II | 1 | RFA (52) |
9 | 53 | F | NO | NA | I | 1 | TACE, 131I (14) |
10 | 58 | M | ALC | A6 | II | 1 | 131I (18) |
11 | 77 | M | HCV | A5 | I | 1 | 131I (16) |
ALC = alcohol; NO = none; HCV = chronic hepatitis C infection; RFA = radiofrequent ablation; HC = hemochromatosis; NA = not applicable because of absence of cirrhosis; TACE = transarterial chemoembolization.